- 询价
- 2025年12月31日
14 年金牌会员
企业认证
相关产品推荐更多 >
万千商家帮你免费找货
0 人在求购买到急需产品
- 详细信息
- 询价记录
- 技术资料
- 相关疾病：
导管癌
- ATCC Number：
CRL-2336™
- 器官来源：
乳房
- 组织来源：
duct
- 年限：
TNM stage IIB, grade 3
- 细胞形态：
上皮样
- 运输方式：
冻存运输
- 生长状态：
贴壁生长
- 物种来源：
人
- 是否是肿瘤细胞：
1
- 库存：
大量
| Designations: | HCC1937 | ||
| Depositors: | AF Gazdar, AK Virmani | ||
| Biosafety Level: | 1 | ||
| Shipped: | frozen | ||
| Medium & Serum: | See Propagation | ||
| Growth Properties: | adherent, The line grows as large epithelial cells with a tendency to float at high cell densities | ||
| Organism: | Homo sapiens | ||
| Morphology: | epithelial |
||
| Source: | Organ: mammary gland; breast Tissue: duct Tumor Stage: TNM stage IIB, grade 3 Disease: primary ductal carcinoma |
||
| Cellular Products: | Epithelial glycoprotein 2 (EGP2) cytokeratin 19 |
||
| Permits/Forms: | In addition to the MTA mentioned above, other ATCC and/or regulatory permits may be required for the transfer of this ATCC material. Anyone purchasing ATCC material is ultimately responsible for obtaining the permits. Please click here for information regarding the specific requirements for shipment to your location. | ||
| Restrictions: | The line is available with the following restrictions: 1. This cell line was deposited at the ATCC by Dr. Adi F. Gazdar and is provided for research purposes only. Neither the cell line nor products derived from it may be sold or used for commercial purposes. Nor can the cells be distributed to third parties for purposes of sale, or producing for sale, cells or their products. The cells are provided as service to the research community. They are provided without warranty of merchantability or fitness for a particular purpose or any other warranty, expressed or implied. 2. Any proposed commercial use of the these cells, or their products must first be negotiated with the University of Texas Southwestern Medical Center at Dallas, 5323 Harry Hines Blvd., Dallas, Texas 75235. Telephone (214) 648-1888, Email TechnologyDevelopment@UTSouthwestern.edu, or Fax: (214) 951-0935. | ||
| Isolation: | Isolation date: October 13, 1995 | ||
| Applications: | BRCA1 analysis revealed that the cell line is homozygous for the BRCA1 5382C mutation, whereas the lymphoblastoid cell line derived from the same patient is heterozygous for the same mutation HCC1937 is positive for the epithelial cell specific marker Epithelial Glycoprotein 2 (EGP2) and for cytokeratin 19 The cells are negative for expression of estrogen receptor (ER) and progesterone receptor (PR) The cells are negative for expression of Her2-neu and for expression of p53. |
||
| Receptors: | estrogen receptor, negative progesterone receptor, negative |
||
| Oncogene: | BRCA1 (mutated, insertion C at nucleotide 5382), her2/neu -, p53 - | ||
| DNA Profile (STR): | Amelogenin: X CSF1PO: 12 D13S317: 13 D16S539: 13,14 D5S818: 12 D7S820: 9,10 THO1: 6 TPOX: 11 vWA: 16,17 |
||
| Cytogenetic Analysis: | CRL-2336 is highly transformed which is evident from the chromosome count and karyotype description. The modal chromosome number is 100. At least forty-three marker chromosomes, involving nearly every chromosome, were found. Chromosome 1 and chromosome 3 derivative chromosomes were verified using commercial whole chromosome paint (fluorescent in-situ hybridization (FISH)) probes. An acrocentric chromosome with an extra C-band at qter was detected (2 copies per metaphase). There were no normal X chromosomes however at least one derivative X was seen in each cell. The absence of a Y chromosome was verified by QM staining and C-bands. Normal copies of N1, N4, N15, N16 and N18 were absent. More detailed cytogenetic information is available upon request. | ||
| Age: | 23 years adult | ||
| Gender: | female | ||
| Ethnicity: | Caucasian | ||
| Comments: | This cell line was initiated from a primary ductal carcinoma on October 13, 1995, and took 11.5 months to establish The tumor was classified as TNM Stage IIB, grade 3 BRCA1 analysis revealed that the cell line is homozygous for the BRCA1 5382C mutation, whereas the lymphoblastoid cell line derived from the same patient is heterozygous for the same mutation This mutation was present in two other family members; an identical sister also developed breast cancer The cell line has an acquired mutation of TP53 with wild-type allele loss; an acquired homozygous deletion of the PTEN gene, and loss of heterozygosity at multiple loci known to be involved in the pathogenesis of breast cancer The cells are negative for expression of Her2-neu and for expression of p53. HCC1937 is positive for the epithelial cell specific marker Epithelial Glycoprotein 2 (EGP2) and for cytokeratin 19 The cells are negative for expression of estrogen receptor (ER) and progesterone receptor (PR) An EBV transformed lymphoblastoid cell line (HCC1937BL) from the same patient is available as ATCC CRL-2337 |
||
| Propagation: | ATCC complete growth medium: The base medium for this cell line is ATCC-formulated RPMI-1640 Medium, Catalog No. 30-2001. To make the complete growth medium, add the following components to the base medium: fetal bovine serum to a final concentration of 10%. Temperature: 37.0°C |
||
| Subculturing: | Protocol: Remove medium, rinse with 0.25% trypsin, 0.03% EDTA solution, add an additional 1 to 2 ml of trypsin solution and allow the flask to set at room temperature (or incubate at 37C) until the cells detach. Add fresh culture medium, aspirate and dispense into new culture flasks. Subcultivation Ratio: A subcultivation ratio of 1:2 to 1:4 is recommended Medium Renewal: Every 2 to 3 days |
||
| Preservation: | Freeze medium: Complete growth medium 95%; DMSO, 5% Storage temperature: liquid nitrogen vapor phase |
||
| Related Products: | Recommended medium (without the additional supplements or serum described under ATCC Medium):ATCC 30-2001 recommended serum:ATCC 30-2020 normal (or near-normal) cell line established from the same patient:ATCC CRL-2337 purified DNA:ATCC CRL-2336D purified RNA:ATCC CRL-2336R cell pellet:ATCC CRL-2336P |
||
| References: | 34277: Tomlinson GE, et al. Characterization of a breast cancer cell line derived from a germ-line BRCA1 mutation. Cancer Res. 58: 3237-3242, 1998. PubMed: 9699648 38266: Gazdar AF, et al. Characterization of paired tumor and non-tumor cell lines established from patients with breast cancer. Int. J. Cancer 78: 766-774, 1998. PubMed: 9833771 |
||
风险提示：丁香通仅作为第三方平台，为商家信息发布提供平台空间。用户咨询产品时请注意保护个人信息及财产安全，合理判断，谨慎选购商品，商家和用户对交易行为负责。对于医疗器械类产品，请先查证核实企业经营资质和医疗器械产品注册证情况。
- 作者
- 内容
- 询问日期
技术资料暂无技术资料 索取技术资料
HCC1937
询价
